Mechanistic Insights into the Ameliorative Effect of Cichoriin on Diabetic Rats-Assisted with an In Silico Approach

Molecules. 2022 Oct 24;27(21):7192. doi: 10.3390/molecules27217192.

Abstract

Type 2 diabetes mellitus is considered to be a substantial socioeconomic burden worldwide on both patients and governments. Coumarins are biomolecules with a diversity of biological activities. The current investigation aimed to explore the ameliorative effects of cichoriin, which is a type of coumarin, on high-fat diet/streptozotocin (HFD/STZ)-induced diabetic rats.

Methods: Rats were allocated into five groups. Group I was considered as the control group, while the other groups were HFD/STZ-induced diabetic rats. Group II was assigned as the diabetic control. Groups III and IV were treated with cichoriin (50 or 100 mg/kg, respectively). Group V received glibenclamide (5 mg/kg) (as a positive control). The blood glucose (BG), serum insulin, triglycerides (TG), total cholesterol (TC), total antioxidant capacity (TAC), catalase, hepatic superoxide dismutase (SOD) and content of malondialdehyde (MDA) were assessed. Histopathological and immunohistochemistry analysis of pancreatic tissue were performed. mRNA and protein expressions of GLUT4, AMPK, and PI3K were estimated.

Results: Cichoriin treatment ameliorated HFD/STZ-induced diabetic conditions and mitigated the histopathological characteristics of the pancreas, as well as increasing pancreatic insulin expression. This decreased the levels of BG, TG, TC, and MDA and improved the TAC, catalase and SOD contents. Cichoriin demonstrated upregulation of mRNA and protein expressions of GLUT4, AMPK, and PI3K. The in silico binding of cichoriin with GLUT4, AMPK, and PI3K supported the possible current activities.

Conclusion: Collectively, this work highlighted the potential role of cichoriin in mitigating HFD/STZ-induced diabetic conditions and showed it to be a valuable product.

Keywords: AMPK; GLUT4; PI3K; SOD; cichoriin; diabetes; streptozotocin.

MeSH terms

  • AMP-Activated Protein Kinases / metabolism
  • Animals
  • Antioxidants / pharmacology
  • Blood Glucose / metabolism
  • Catalase / metabolism
  • Diabetes Mellitus, Experimental* / metabolism
  • Diabetes Mellitus, Type 2* / metabolism
  • Hypoglycemic Agents / pharmacology
  • Hypoglycemic Agents / therapeutic use
  • Insulins*
  • Phosphatidylinositol 3-Kinases / metabolism
  • RNA, Messenger
  • Rats
  • Streptozocin
  • Superoxide Dismutase / metabolism
  • Triglycerides

Substances

  • Catalase
  • cichoriin
  • AMP-Activated Protein Kinases
  • Streptozocin
  • Blood Glucose
  • Antioxidants
  • Superoxide Dismutase
  • Triglycerides
  • Phosphatidylinositol 3-Kinases
  • RNA, Messenger
  • Insulins
  • Hypoglycemic Agents